LINDIS Biotech Announces Online Publication of Abstract on Trifunctional Antibody CATUMAXOMAB for the Treatment of High-Risk Non-Muscle-Invasive Bladder Cancer at the ASCO 2022 Annual Meeting tennesseedaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tennesseedaily.com Daily Mail and Mail on Sunday newspapers.
Observed Preliminary Efficacy and Safety together with High Complete Remission Rate Strengthens Evidence of Therapy's Potential MARTINSRIED, GERMANY / ACCESSWIRE / June 1, 2022 / LINDIS Biotech GmbH, a